Ohio State Navbar

Sign In

RSS Feed Research News


New funding opportunities from NIH Common Fund 

 

The NIH Common Fund announced new funding opportunities in Metabolomics, Single Cell Analysis, and Regulatory Science. 

Please note that letters of intent are due in December or early January for most of these opportunities.

Increasing Metabolomics Research Capacity
Five new funding opportunities to address the need for new technology, infrastructure, and training to accelerate the capabilities and application of metabolomics in basic, clinical, and translational research. Three announcements have an application receipt date of January 31, 2012 and two have an application receipt date of Feb. 15, 2012. When requested, Letters of Intent are due one month prior to the receipt date.

  • Technology Development to Enable Large Scale Metabolomics Analyses (R01), RFA-RM-11-019:
    • Develop novel technologies that address current limitations in sample handling and preparation; sample throughput, resolution, and quantitation; and identification of specific chemical species; and other current technological constraints.
    • Technologies to be applicable across a wide range of basic mechanistic, clinical, and/or translational research, and be suitable for use by high capacity research cores and the broader metabolomics research community.
    • Total funds available approximately $10 million for awards up to 5 years.
    • Application receipt date – Jan. 31, 2012; Letter of Intent due date – Dec. 31, 2011.
  • The Development of Courses or Workshops in Metabolomics (R25), RFA-RM-11-018:

  • Develop and implement innovative courses or workshops to advance the use of metabolomics in translational research and to support interdisciplinary teams for metabolomics studies.
  • Courses directed at all levels of students, from undergraduates to experienced investigators.
  • Budgets up to $50,000 in direct costs for the first year of planning, and up to $100,000 in years 2 to 5 for implementation.
  • Application receipt date – Jan. 31, 2012; Letter of Intent due date – Dec. 31, 2011.
  • Mentored Research Scientist Development Award in Metabolomics (K01), RFA-RM-11-017:

  • Support to provide intensive research training in metabolomics under the guidance of an experienced mentor with an established research record in metabolomics.
  • Eligible candidates include postdoctoral and clinical fellows or investigators who meet the definition of an NIH “new investigator.”
  • Budgets up to $75,000 per year towards salary plus any fringe benefits, and up to $50,000 per year toward research development for awards up to 5 years.
  • Application receipt date – Jan. 31, 2012.
  • Regional Comprehensive Metabolomics Resource Cores (RCMRC) (U24), RFA-RM-11-016:

  • Establish Regional Comprehensive Metablomics Resource Cores (RCMRCs) to increase national capacity for utilizing metabolomics in biomedical research and enhance collaboration.
  • RCMRCs to provide metabolomics profiling and data analysis services to basic, translational, and clinical investigators in the broad biomedical research community.
  • Projects may include pilot/feasibility projects, training activities, outreach and other dissemination activities.
  • Approximately $53 M for FY2012-FY2017 for individual awards up to 5 years.
  • Application receipt dates – Feb. 15, 2012, Feb. 15, 2013; Letter of Intent due dates – Jan. 13, 2012, Jan. 15, 2013.
  • Metabolomics Data Repository and Coordinating Center (DRCC) (U01), RFA-RM-11-020:

  • Establish a coordinating center and data repository for the Metabolomics program  and metabolomics research community.
  • Goal to enhance metabolomics research by disseminating data broadly to researchers in the metabolomics community. 
  • DRCC to store published primary data for examination and analysis with high performance computation methods in a cloud computing environment, help develop data access and analytical tools, and contribute to the coordination of domestic and international metabolomics efforts.Approximately
  • $6M for FY2012-2016 for one award up to 5 years. 
  • Application receipt date – Feb. 15, 2012; Letter of Intent due date – Jan. 15, 2012.


Single Cell Analysis:
Three new funding opportunities to accelerate the development and application of single cell analysis technologies in basic, clinical, and translational research.  All three announcements have an application receipt date of January 23, 2012, with the Letter of Intent due on December 23, 2011. 

  • Studies to Evaluate Cellular Heterogeneity Using Transcriptional Profiling of Single Cells (U01), RFA-RM-11-013:
    • Studies to evaluate cellular heterogeneity and characterize natural variability (“noise”) using transcriptional profiling of single human cells.
    • Goal to fuel fundamental discoveries about the nature of cells and the impact of microenvironments, stimulate new technology to enable transcriptional analyses, and facilitate data sharing and comparison of data across tissues.
    • No budget cap for individual proposals. Approximately $4M per year for awards up to 5 years.
  • Exceptionally Innovative Tools and Technologies for Single Cell Analysis (R21), RFA-RM-11-014:

  • Develop “quantum leap” improvements in next-generation, innovative technologies to improve the analysis of cell heterogeneity, spatiotemporal characteristics, sensitivity, specificity, and number of analyses per cell.
  • Goal to develop proof-of-concept tools with the potential to transform the field of single cell research by verifying their feasibility in a complex biological tissue or living organism.
  • Preliminary data not required.
  • Budgets up to $275,000 direct costs over 2 years with no more than $200,000 in direct costs in any single year.
  • Accelerating the Integration and Translation of Technologies to Characterize Biological Processes at the Single Cell Level (R01), RFA-RM-11-015

  • Studies to accelerate the translation of promising technologies for single cell analysis from “lab prototype to clinical application” by extending the parameter space and spatiotemporal resolution.
  • Focus on improvements to technological innovations that have already been demonstrated in principle and have potential to offer significant advantages over existing approaches.
  • Validation of expected performance of the technology in a large, functional cell population of human or model animal cells required.
  • Emphasis on multidisciplinary project teams.
  • Budgets may be up to $750,000 in direct costs per year up to 5 years.


Regulatory Science:
Two funding announcements to advance technology development to streamline drug development. Program represents a collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration (FDA). Both funding announcements have an application receipt date of January 26, 2012 with the Letter of Intent due on December 26, 2011.

  • Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3), RFA-RM-11-022

  • Development of human microsystems, or organ “chips,” that are representative of major organs and tissues in the body and can be integrated together to model the connection between different organ systems in the human.
  • Goal to establish microsystems for use in drug screening for safety and efficacy more rapidly and efficiently than current methods.
  • Phased award mechanism: UH2 award budgets expected $450,000-$675,000, may not exceed $1.25 million in direct costs per year for up to 2 years.  Budget for UH3 phase should reflect complexity of project.

  • Stem/Progenitor Cell-Derived Human Micro-organs and –Tissues (U18),  RFA-RM-12-001:

  • Development of multi-cellular models (microsystems) that represent the disease pathogenesis, cellular diversity, genomic complexity, microenvironment, and functional output of human organ systems.
  • Microsystems developed using advancements in stem- and progenitor-derived cell differentiation protocols, and 3D in vitro culturing techniques.
  • Budgets up to $200,000-$250,000 in direct costs per year for up to 2 years.


The NIH Common Fund (formerly the NIH Roadmap) encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs. These programs are supported by the Common Fund, and managed by the NIH Office of the Director in partnership with the various NIH Institutes, Centers and Offices.

 

Posted on 9-Dec-11 by Gengler-Nowak, Karla
Tags:
 
Trackback Url  |  Link to this post | Bookmark this post with: